3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Endometrial Neoplasms
10
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer (LARC)
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Mouth Neoplasms
1
Interventions
Doxorubicin
69
Radiotherapy
50
Ifosfamide
48
Gemcitabine
43
Cyclophosphamide
36
pazopanib
29
Filgrastim
28
pembrolizumab
26
Docetaxel
26
Nivolumab
23
Surgical Procedures, Operative
21
Etoposide
21
Cisplatin
21
Trabectedin
19
Blood Specimen Collection
19
Carboplatin
15
Radiation
14
Magnetic Resonance Spectroscopy
14
Vincristine
13
Bevacizumab
13
anlotinib
12
Temozolomide
12
Peripheral Blood Stem Cell Transplantation
12
Ipilimumab
12
liposomal doxorubicin
11
apatinib
11
Radiosurgery
11
Neoadjuvant Therapy
11
Melphalan
11
Surveys and Questionnaires
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sarcoma
×
dostarlimab
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled